Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947083 · ClinicalTrials.gov registry record · Phase 2
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
A Phase 2 study of Myeloma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06947083: Recruiting Phase 2 study of Myeloma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06947083 is a Phase 2 study of Myeloma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 39 participants, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06947083, a Phase 2 study of Myeloma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.
Primary Outcome
Progression-free survival (PFS) is measured from the date of initiation of Elranatamab (i.e., on-treatment date) to either the date of death from any cause or the date of disease progression, whichever comes first.
Conditions Studied
Interventions
- DRUG Elranatamab
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2029-04 |
| Phase | Phase 2 |
What NCT06947083 shows while recruiting
NCT06947083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab is the first listed.
NCT06947083 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06947083 about?
NCT06947083 is a clinical study titled "Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma". The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, define...
What is the current status of trial NCT06947083?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2025-05-27. Estimated completion is 2029-04.
What conditions does trial NCT06947083 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT06947083?
The interventions under investigation include: Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06947083?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947083 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06947083's enrollment target sits among peer trials
39 22nd of 29 higher than 8 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI